← Compound index
COMPOUND RECORD / ZHENOLUTEN

ZhenolutenЖенолутен

A peptide mixture described in the Russian report as calf or pig ovary extract. A translated edition gives a conflicting tissue source.

Source linked

What the studies found

Comparison in people · 2019

Zhenoluten and Endoluten in women with reduced reproductive function

Study of multiple preparations

Anti-Müllerian hormone at month four
1.16 ± 0.18 ng/mL with the combination versus 0.82 ± 0.24 with placebo. Baselines were 0.76 ± 0.13 and 0.74 ± 0.12 ng/mL, respectively.
Estradiol at month four
616.24 ± 69.42 pmol/L with the combination versus 209.26 ± 12.64 with placebo.
Pregnancies reported by months four through eight
180/214 (84%) with the combination versus 8/62 (13%) with placebo. The expanded report supplies no live-birth outcomes or detailed follow-up accounting.

In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.

Study notes · methods, sources and limitations

Participants or model 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.

Design From 2013 to 2018, the Moscow center enrolled 276 women aged 34–38. The 214-person combination arm received oral Zhenoluten 20 mg each morning and Endoluten 10 mg every 72 hours for four months. The 62-person comparison received placebo. Neither group received hormone therapy.

Important limitations

  • Group assignment and masking are unspecified. The report combines two products, so the effect of either alone is unknown. The pregnancy figures come from the authors’ expanded report. Live births, completeness of follow-up and maternal or neonatal safety data are unavailable. The conference methods and expanded report agree on every-72-hour Endoluten. A recommendation elsewhere in the conference reproduction gives a different schedule.
  • The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The differences come from a comparison with unspecified allocation and masking.

9th European Congress of the International Association of Gerontology and Geriatrics, Gothenburg, 2019. Author material reproduced by Peptides. · Conference report and expanded author report

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Comparison in people · 2011

Zhenoluten: institute clinical report (commercially hosted translation)

The report describes symptom and hormone changes during adjunctive treatment.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 67 women: 39 with climacteric symptoms and 28 with early ovarian insufficiency; four comparison groups

Important limitations

  • Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated. Group-specific denominators are unclear. The translated identity paragraph says triceps tissue despite an ovarian target; the original formulation must be checked. Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.

Institute-attributed report, 2011; commercially hosted brochure pp. 34–35 · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Zhenoluten

Identity / background source ↗

Research background

Zhenoluten is an ovarian tissue peptide preparation. A Medical Center report followed women with climacteric symptoms or early ovarian insufficiency. A separate 276-person report studied Zhenoluten together with Endoluten.

Compound class
Archival preparation lead
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

67 women: 39 with climacteric symptoms and 28 with early ovarian insufficiency; four comparison groups

Study methods

Small adjunctive comparison; signed original, allocation and reporting require verification

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

New indexed primary abstracts and/or report reproductions linked; review depth shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2019

Zhenoluten and Endoluten in women with reduced reproductive function

In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.

Study notes and original source
2019Human comparative studyRussian-language source

Zhenoluten and Endoluten in women with reduced reproductive function

Oral ovarian and pineal polypeptide combination · Conference report and expanded author report

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 9th European Congress of the International Association of Gerontology and Geriatrics, Gothenburg, 2019. Author material reproduced by Peptides.

In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.

Results and tables

Reported findings and study design

From 2013 to 2018, the Moscow center enrolled 276 women aged 34–38. The 214-person combination arm received oral Zhenoluten 20 mg each morning and Endoluten 10 mg every 72 hours for four months. The 62-person comparison received placebo. Neither group received hormone therapy.

Population or model 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.

Results · Expanded report by the congress authors, Tables 1–3, matched to the conference cohort
MeasureResultComparison, timing and statistics
Anti-Müllerian hormone at month four1.16 ± 0.18 ng/mL with the combination versus 0.82 ± 0.24 with placebo. Baselines were 0.76 ± 0.13 and 0.74 ± 0.12 ng/mL, respectively.
Estradiol at month four616.24 ± 69.42 pmol/L with the combination versus 209.26 ± 12.64 with placebo.
Pregnancies reported by months four through eight180/214 (84%) with the combination versus 8/62 (13%) with placebo. The expanded report supplies no live-birth outcomes or detailed follow-up accounting.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The differences come from a comparison with unspecified allocation and masking.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
Source reviewed
Conference reproduction, PDF pages 21–22, and expanded author report, Tables 1–3. Both describe the same participants.
Study limitations
  • Group assignment and masking are unspecified. The report combines two products, so the effect of either alone is unknown.
  • The pregnancy figures come from the authors’ expanded report. Live births, completeness of follow-up and maternal or neonatal safety data are unavailable.
  • The conference methods and expanded report agree on every-72-hour Endoluten. A recommendation elsewhere in the conference reproduction gives a different schedule.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2011

Zhenoluten: institute clinical report (commercially hosted translation)

The report describes symptom and hormone changes during adjunctive treatment.

Study notes and original source
2011Human comparative studyFull text available

Zhenoluten: institute clinical report (commercially hosted translation)

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

Format: PDF · Reviewed: Report reproduction reviewed

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 34–35

The report describes symptom and hormone changes during adjunctive treatment.

Population / setting
67 women: 39 with climacteric symptoms and 28 with early ovarian insufficiency; four comparison groups
Source reviewed
Brochure PDF pp. 34–35: methods/results text checked; selected population/table pages visually inspected. This is a provenance check, not authentication of the institute original.
Study limitations
  • Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
  • Group-specific denominators are unclear. The translated identity paragraph says triceps tissue despite an ovarian target; the original formulation must be checked.
  • Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.

Reviewed 2026-10-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗